drugset
drugset / Trial / NCT05152173

Efficacy, Safety, and Tolerability, of EN3835 vs Placebo in the Treatment of Plantar Fibromatosis

NCT05152173 ↗

Phase 2 Completed 176 enrolled Endo USA Inc., a Keenova Therapeutics Company
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of up to 2 treatments of EN3835 vs placebo in participants with plantar fibromatosis.

Timeline

Start
2021-11-29
Primary completion
2023-01-10
Completion
2023-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Collagenase Clostridium Histolyticum Protein / enzyme biologic 1.8 mg —

Indications

plantar fibromatosis